Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPOX + Bevacizumab + Tislelizumab in Advanced Gastroesophageal Adenocarcinoma
NCT05299476Phase 2Completed
- Sponsor
- Chinese PLA General Hospital
- Start
- Apr 2022
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, bevacizumab in gastroesophageal adenocarcinoma, sponsored by Chinese PLA General Hospital. Started Apr 2022; status: completed.
02
Drugs
tislelizumabbevacizumab
03
Conditions
gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on NCT05299476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05299476.